Dernières nouvelles pour Danaher (NYSE:DHR) Stock

DANAHER CORP

Danaher

In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 1.01% on an annualized basis producing an average annual return of 12.77%. Currently, Danaher has a market capitalization of $147.79 billion. 
Buying $1000 In DHR: If an investor had bought $1000 of DHR stock 10 years ago, it would be worth $3,343.02 today based on a price of $206.40 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753887616_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) has outperformed the market over the past 10 years by 1.09% on an annualized basis producing an average annual return of 12.78%. Currently, Danaher has a market capitalization of $147.13 billion. 
Buying $100 In DHR: If an investor had bought $100 of DHR stock 10 years ago, it would be worth $336.44 today based on a price of $205.48 for DHR at the time of writing.
<h3>Danaher's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1753487114_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today

UBS analyst Dan Leonard maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and lowers the price target from $240 to $225.

Price Target

Analyst Ratings

UBS Maintains Buy on Danaher, Lowers Price Target to $225

WIIM

Danaher shares are trading higher after the company on Tuesday reported better-than-expected Q2 results and raised FY25 guidance.

Wells Fargo analyst Brandon Couillard maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Equal-Weight and lowers the price target from $210 to $205.

Wells Fargo Maintains Equal-Weight on Danaher, Lowers Price Target to $205

Guggenheim analyst Subbu Nambi reiterates Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and maintains $250 price target.

Reiteration

Guggenheim Reiterates Buy on Danaher, Maintains $250 Price Target

Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>)&nbsp;on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $5.84 billion</a>.&nbsp;
The life science giant reported adjusted earnings of $1.80 per share, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46538741/danaher-reports-second-quarter-2025-results" rel="noreferrer noopener">beating the consensus of $1.64</a>.
Non-GAAP core revenue increased 1.5% year over year, compared to the expectations of a growth in <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44921061/danaher-beats-q1-expectations-signals-caution-ahead-in-unusual-times" rel="noreferrer noopener">low single digits</a> year over year.
Operating cash flow was $1.3 billion, and non-GAAP&nbsp;free cash flow was $1.1 billion.
Danaher's second-quarter adjusted operating profit margin of 27.3% exceeded expectations of around 25.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966205/analyst-sees-opportunity-in-danaher-stock-as-sentiment-improves" rel="noreferrer noopener">Analyst Sees Opportunity In Danaher Stock As Sentiment Improves</a>
Biotechnology&nbsp;<a target="_blank" href="https://filecache.investorroom.com/mr5ir_danaher/934/Q2%202025%20Danaher%20Earnings%20Presentation.pdf" rel="noreferrer noopener">sales</a> increased to $1.85 billion compared to $1.71 billion a year ago, with core growth of 6%.
Sales in the Life Sciences segment remained flat at $1.78 billion, and diagnostic sales increased from $2.26 billion to $2.31 billion.
The company said, "DBS-driven execution, paired with another quarter of +HSD growth in Bioprocessing and disciplined cost management, enabled us to exceed our Q2 adjusted EPS and cash flow expectations."
<h2 class="wp-block-heading">Guidance</h2>
Danaher raised fiscal 2025 adjusted earnings guidance from $7.60-$7.75 per share to $7.70-$7.80, compared to the consensus of $7.70. The company cites good traction on cost initiatives.
Danaher&nbsp;<a target="_blank" href="https://investors.danaher.com/image/Q1+2025+Earnings+Supplement.pdf" rel="noreferrer noopener">reaffirms</a> that in fiscal year 2025, non-GAAP core revenue will grow by approximately 3% year over year.
Cepheid 2025 respiratory revenues will be around&nbsp;$1.7 billion.
The company expects an adjusted operating profit margin of around 25.5%.
Biotechnology core revenue growth is expected to be approximately 6% for the third quarter of 2025 and around 7% for the fiscal year 2025.
Life sciences core revenue will remain flat for the third quarter and fiscal year 2025.
Diagnostics sales are expected to increase in the low single digits in the third quarter and flat to low single digits in fiscal year 2025.
<h2 class="wp-block-heading">Management update</h2>
Danaher announced Matthew Gugino, currently group CFO of Life Sciences Innovations Group and VP of Financial Planning &amp; Analysis, will succeed Matthew McGrew as Danaher's CFO, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/07/n46538769/danaher-announces-transition-plan-for-chief-financial-officer" rel="noreferrer noopener">effective February 28, 2026</a>.
<h2 class="wp-block-heading">Analyst Opinion</h2>
William Blair writes that the macro backdrop for life science tools and bioprocessing companies was anything but sanguine in the second quarter, with escalating concerns surrounding the funding environment, tariffs, MFN, and whether these uncertainties resulted in a slowdown in the overall demand environment."
Danaher's results suggest that was not the case, at least in the second quarter, particularly within bioprocessing. Analyst Matt Larew maintains<a target="_blank" href="https://www.benzinga.com/quote/DHR/analyst-ratings" rel="noreferrer noopener"> the Outperform rating</a>.
Price Action: DHR stock is trading 0.68% higher at $189.34 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/07/46548132/marlboro-parent-philip-morris-internationals-smoke-free-segment-powers-q2-gains" target="_blank" rel="noreferrer noopener">Marlboro Parent Philip Morris International's Smoke-Free Segment Powers Q2 Gains</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Earnings

Large Cap

Guidance

Health Care

General

Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline

It was a quiet Tuesday on Wall Street, as major indexes edged lower with investors pausing ahead of a critical <a href="https://www.benzinga.com/topic/magnificent-seven">wave of tech earnings.</a>
By midday trading in New York, the S&amp;P 500 dipped 0.1% and the Nasdaq 100 slipped 0.5%, pulling back after hitting fresh all-time highs on Monday. The Russell 2000 outperformed, rising 0.6%.
Weak corporate results weighed on sentiment. Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) plunged 9.5% after missing revenue forecasts. Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) dropped more than 8% on a double miss, and General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) lost 5.5% after warning of a steeper-than-expected tariff hit in the second half of 2025.
Health care led sector gains, while tech stocks lagged, as attention turns to earnings from Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), and Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) which are slated to report earnings on Wednesday. 
On the macro front, Treasury Secretary Scott Bessent said the U.S. will meet with Chinese officials next week to continue trade negotiations. That raised hopes for an extension to the August 12 China tariff deadline.
In the bond market, the 10-year Treasury yield fell for a fifth straight session to 4.33%, its lowest level in over a week. Meanwhile, the U.S. dollar index dropped 0.4%, extending its slide for a third day.
Gold climbed 0.9% to $3,420 per ounce, the highest since June 16, as uncertainty surrounding the Federal Reserve's independence and Chair Jerome Powell's future fueled safe-haven demand.
In crypto, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.4% to $119,000, extending its rebound alongside broader market hedging flows.
Read also:<a href="https://www.benzinga.com/markets/macro-economic-events/25/07/46549915/el-erian-powell-trump-resign-fed-independence-scott-bessent"> El-Erian Says Powell Should Resign—To Save The Fed Itself</a>
<h3 class="wp-block-heading">Tuesday&#8217;s Performance Of Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,243.42</td>
<td>0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,378.27</td>
<td>0.1%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,300.18</td>
<td>-0.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>23,073.22</td>
<td>-0.5%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) eased 0.2% to $557.08.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) flattened at $443.63.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;eased 0.6% to $560.86.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.6% at $222.67.</li>
<li>The&nbsp;Health Care&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) outperformed, up 1.3%; the&nbsp;Technology&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) lagged, down 0.7%.</li>
</ul>
<h3 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h3>
Stocks reacting on earnings reports included: 
<ul class="wp-block-list">
<li>D.R. Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>), up 14.5%</li>
<li>Northrop Grumman Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), up 8.4%</li>
<li>PACCAR Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>), up 4.7%</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>), down 6.8%</li>
<li>RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), down 2.5%</li>
<li>Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), down 1.0%</li>
<li>Danaher Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), down 0.3%</li>
<li>Equifax Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>), down 7.2%</li>
<li>IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) up 18%, </li>
<li>Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) up 1.5%</li>
<li>PulteGroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) up 9.4%</li>
<li>KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) up 1.6%</li>
<li>Quest Diagnostics Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) up 6.3%</li>
<li>Halliburton Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) up 0.4%</li>
<li>Genuine Parts Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) up 5.5%</li>
<li>Tenet Healthcare Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) down 4.3%</li>
<li>Avery Dennison Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) up 0.3%</li>
<li>Invesco Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) up 4.1%</li>
<li>Mueller Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLI#NYSE">MLI</a>) up 0.5%</li>
<li>Old National Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) down 1.2%</li>
<li>Valmont Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) up 5.1%</li>
<li>Badger Meter Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) down 13.8% </li>
<li>Medpace Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDP#NASDAQ">MEDP</a>), up 53.2%</li>
</ul>
Companies slated to report earnings after the close include Intuitive Surgical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>), Texas Instruments Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), Capital One Financial Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>), CoStar Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>), EQT Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>), Enphase Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) and East West Bancorp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>). 
Read now:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/07/46543934/formula-1-liberty-fwonk-stock-goldman-sachs-forecasts">Formula 1 Is Wall Street&#8217;s New Money Machine—With Horsepower </a></li>
</ul>
Image: Shutterstock

Equities

Broad U.S. Equity ETFs

Commodities

Economics

Tech

ETFs

$BTC

CSGP

SPDR Dow Jones Industrial Average ETF Trust

ENPH

EWBC

GOOGL

ISRG

MEDP

MSCI

PCAR

TSLA

Lockheed, General Motors Tumble, Gold Hits 1-Month Highs: What's Moving Markets Tuesday?

DHR stock has given up its prior loss. Danaher shares were trading lower following Q2 reported financial results.

Danaher shares are trading lower following Q2 reported financial results.

Management

Danaher Announced That Matthew Gugino, Currently Group Chief Financial Officer Of The Company's Life Sciences Innovations Group And Vice President Of Financial Planning & Analysis, Will Succeed Matthew Mcgrew As Danaher's Chief Financial Officer Effective February 28, 2026

Third Quarter and Full Year 2025 Outlook
With respect to forecasted core sales growth and adjusted diluted net earnings per common share, the Company does not reconcile either of these non-GAAP measures to its respective, comparable measure prepared in accordance with U.S generally accepted accounting principles (GAAP) because (except for estimated amortization of acquisition-related intangible assets of $1.7 billion for the year ending December 31, 2025 and estimated currency translation contributions to revenue growth of 1.5% (for the third quarter 2025) and 1.0% (for the full year 2025), assuming the currency exchange rates in effect as of June 27, 2025) the additional elements that would be reflected in any such GAAP measures (such as the impact of currency exchange rates on profitability, acquisitions, divested product lines, discrete tax adjustments, impairments and gains and losses on investments) are difficult to predict and estimate and are often dependent on future events that may be uncertain or outside of our control.&nbsp; The impact of these additional elements could be material to our results computed in accordance with GAAP.
For the third quarter 2025, the Company anticipates that non-GAAP core revenue will grow low-single digits year-over-year.
For full year 2025, there is no change to the Company's expectation that non-GAAP core revenue will grow approximately 3% year-over-year.&nbsp; The Company is also increasing its full year adjusted diluted net earnings per common share guidance to a range of $7.70 to $7.80 versus previous guidance of $7.60 to $7.75.

Danaher Raises FY2025 Adj EPS Guidance from $7.60-$7.75 to $7.70-$7.80 vs $7.70 Est

Danaher Q2 2025 Adj. EPS $1.80 Beats $1.64 Estimate, Sales $5.94B Beat $5.84B Estimate

<h3>Companies Reporting Before The Bell</h3>
• PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) is expected to report quarterly earnings at $2.97 per share on revenue of $4.40 billion. 
• RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) is expected to report quarterly earnings at $1.44 per share on revenue of $20.64 billion. 
• Hope Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOPE#NASDAQ">HOPE</a>) is likely to report quarterly earnings at $0.21 per share on revenue of $131.11 million. 
• General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) is likely to report quarterly earnings at $2.41 per share on revenue of $45.57 billion. 
• D.R. Horton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>) is estimated to report quarterly earnings at $2.91 per share on revenue of $8.79 billion. 
• Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) is estimated to report quarterly earnings at $2.86 per share on revenue of $5.16 billion. 
• Northrop Grumman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) is likely to report quarterly earnings at $6.69 per share on revenue of $10.12 billion. 
• Lockheed Martin (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) is likely to report quarterly earnings at $6.54 per share on revenue of $18.57 billion. 
• Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) is projected to report quarterly earnings at $0.39 per share on revenue of $1.10 billion. 
• Synchrony Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYF#NYSE">SYF</a>) is estimated to report quarterly earnings at $1.71 per share on revenue of $4.03 billion. 
• Philip Morris Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>) is projected to report quarterly earnings at $1.85 per share on revenue of $10.30 billion. 
• Complete Solaria (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) is projected to report quarterly loss at $0.01 per share on revenue of $85.00 million. 
• PACCAR (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>) is expected to report quarterly earnings at $1.34 per share on revenue of $6.95 billion. 
• MSCI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) is projected to report quarterly earnings at $4.12 per share on revenue of $767.15 million. 
• Old National (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONB#NASDAQ">ONB</a>) is likely to report quarterly earnings at $0.51 per share on revenue of $622.93 million. 
• The Interpublic Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IPG#NYSE">IPG</a>) is expected to report quarterly earnings at $0.56 per share on revenue of $2.16 billion. 
• Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) is expected to report quarterly earnings at $0.56 per share on revenue of $5.43 billion. 
• Avery Dennison (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVY#NYSE">AVY</a>) is likely to report quarterly earnings at $2.41 per share on revenue of $2.23 billion. 
• MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) is projected to report quarterly earnings at $0.42 per share on revenue of $288.14 million. 
• Capital City Bank Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCBG#NASDAQ">CCBG</a>) is likely to report quarterly earnings at $0.80 per share on revenue of $62.25 million. 
• Valmont Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) is projected to report quarterly earnings at $4.76 per share on revenue of $1.03 billion. 
• Sherwin-Williams (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHW#NYSE">SHW</a>) is projected to report quarterly earnings at $3.79 per share on revenue of $6.30 billion. 
• Pentair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNR#NYSE">PNR</a>) is likely to report quarterly earnings at $1.33 per share on revenue of $1.11 billion. 
• Peoples Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEBO#NASDAQ">PEBO</a>) is projected to report quarterly earnings at $0.77 per share on revenue of $113.08 million. 
• Mercantile Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBWM#NASDAQ">MBWM</a>) is projected to report quarterly earnings at $1.24 per share on revenue of $60.17 million. 
• Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) is likely to report quarterly earnings at $0.83 per share on revenue of $12.57 billion. 
• KeyCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEY#NYSE">KEY</a>) is estimated to report quarterly earnings at $0.34 per share on revenue of $1.80 billion. 
• IQVIA Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) is expected to report quarterly earnings at $2.66 per share on revenue of $3.96 billion. 
• Genuine Parts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPC#NYSE">GPC</a>) is projected to report quarterly earnings at $2.07 per share on revenue of $6.11 billion. 
• Forestar Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOR#NYSE">FOR</a>) is expected to report quarterly earnings at $0.77 per share on revenue of $395.20 million. 
• First BanCorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBP#NYSE">FBP</a>) is projected to report quarterly earnings at $0.46 per share on revenue of $251.62 million. 
• Equifax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EFX#NYSE">EFX</a>) is expected to report quarterly earnings at $1.92 per share on revenue of $1.51 billion. 
• Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) is expected to report quarterly earnings at $1.64 per share on revenue of $5.84 billion. 
• Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) is expected to report quarterly earnings at $2.57 per share on revenue of $2.72 billion. 
• Community Financial Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBU#NYSE">CBU</a>) is expected to report quarterly earnings at $1.02 per share on revenue of $202.48 million. 
• Badger Meter (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMI#NYSE">BMI</a>) is projected to report quarterly earnings at $1.22 per share on revenue of $235.90 million. 
<h3>Companies Reporting After The Bell</h3>
• Orrstown Financial Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORRF#NASDAQ">ORRF</a>) is expected to report quarterly earnings at $0.98 per share on revenue of $51.98 million. 
• Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) is expected to report quarterly earnings at $1.93 per share on revenue of $2.35 billion. 
• Core Natural Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNR#NYSE">CNR</a>) is expected to report quarterly earnings at $1.90 per share on revenue of $4.34 billion. 
• Capital One Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) is projected to report quarterly earnings at $3.56 per share on revenue of $12.51 billion. 
• Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) is estimated to report quarterly earnings at $0.62 per share on revenue of $358.02 million. 
• Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) is expected to report quarterly earnings at $1.13 per share on revenue of $263.49 million. 
• PennyMac Financial Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFSI#NYSE">PFSI</a>) is projected to report quarterly earnings at $3.07 per share on revenue of $551.41 million. 
• Matador Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTDR#NYSE">MTDR</a>) is estimated to report quarterly earnings at $1.34 per share on revenue of $905.51 million. 
• Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) is estimated to report quarterly earnings at $0.65 per share on revenue of $714.71 million. 
• Northpointe Bancshares (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPB#NYSE">NPB</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $57.61 million. 
• EQT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQT#NYSE">EQT</a>) is projected to report quarterly earnings at $0.43 per share on revenue of $1.78 billion. 
• Canadian National Railway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNI#NYSE">CNI</a>) is expected to report quarterly earnings at $1.37 per share on revenue of $3.16 billion. 
• Pegasystems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) is estimated to report quarterly earnings at $0.19 per share on revenue of $367.24 million. 
• PennyMac Mortgage IT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PMT#NYSE">PMT</a>) is projected to report quarterly earnings at $0.36 per share on revenue of $94.33 million. 
• Chubb (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CB#NYSE">CB</a>) is likely to report quarterly earnings at $5.92 per share on revenue of $13.45 billion. 
• East West Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWBC#NASDAQ">EWBC</a>) is likely to report quarterly earnings at $2.23 per share on revenue of $700.82 million. 
• CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $771.82 million. 
• Karooooo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $71.47 million. 
• SAP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) is likely to report quarterly earnings at $1.63 per share on revenue of $10.39 billion. 
• Weatherford International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFRD#NASDAQ">WFRD</a>) is likely to report quarterly earnings at $0.98 per share on revenue of $1.19 billion. 
• Vicor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VICR#NASDAQ">VICR</a>) is projected to report quarterly earnings at $0.18 per share on revenue of $96.43 million. 
• Usana Health Sciences (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USNA#NYSE">USNA</a>) is likely to report quarterly earnings at $0.54 per share on revenue of $225.20 million. 
• Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) is estimated to report quarterly earnings at $1.32 per share on revenue of $4.31 billion. 
• Trustmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMK#NASDAQ">TRMK</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $200.74 million. 
• Renasant (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNST#NYSE">RNST</a>) is projected to report quarterly earnings at $0.74 per share on revenue of $262.07 million. 
• National Bank Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBHC#NYSE">NBHC</a>) is expected to report quarterly earnings at $0.80 per share on revenue of $109.81 million. 
• KKR Real Est Finance Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KREF#NYSE">KREF</a>) is projected to report quarterly loss at $0.07 per share on revenue of $31.90 million. 
• Hanmi Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) is likely to report quarterly earnings at $0.61 per share on revenue of $65.58 million. 
• First Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRBA#NASDAQ">FRBA</a>) is expected to report quarterly earnings at $0.42 per share on revenue of $35.27 million. 
• Cathay General (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CATY#NASDAQ">CATY</a>) is likely to report quarterly earnings at $1.10 per share on revenue of $196.36 million. 
• Cal-Maine Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) is expected to report quarterly earnings at $5.29 per share on revenue of $877.03 million. 
• First Busey (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUSE#NASDAQ">BUSE</a>) is likely to report quarterly earnings at $0.62 per share on revenue of $193.20 million. 
• Baker Hughes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NASDAQ">BKR</a>) is estimated to report quarterly earnings at $0.55 per share on revenue of $6.63 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BUSE

CALM

CATY

CCBG

FRBA

HAFC

HOPE

KARO

KREF

MANH

MBWM

MMYT

MTDR

NBHC

ORRF

PEBO

PEGA

PFSI

RNST

SPWR

TRMK

USNA

VICR

WFRD

Earnings Scheduled For July 22, 2025

Wall Street opened the week on a risk-on footing, with the S&amp;P 500 and the Nasdaq 100 extending record highs as strong earnings reinforced confidence in corporate America and investors continued to <a href="https://www.benzinga.com/topic/tariffs">shrug off trade tensions.</a>
By midday trading in New York, the S&amp;P 500 had climbed 0.6% to break above 6,330, the Nasdaq 100 rose 0.8% to 23,260, and the Dow Jones added 260 points, or 0.6%. 
Commerce Secretary Howard Lutnick reaffirmed the August 1 tariff deadline as &#8220;hard,&#8221; though he said that negotiation are set to continue.
See Also: <a href="https://www.benzinga.com/markets/economic-data/25/07/46521011/trump-stocks-bonds-foreign-inflows-record">Trump&#8217;s Economy Is Riding A Tsunami Of Inflows — So Much For &#8216;Sell America&#8217;</a>
Gold prices jumped 1.5% to $3,400 per ounce, hitting a one-month-high, while silver gained 1.9%, both lifted by renewed dollar weakness.
The U.S. dollar index slipped below 98 amid rising concerns over the Fed's independence. On Monday, Treasury Secretary Scott Bessent called for a review of the institution, telling CNBC that there's a need to "examine the entire Federal Reserve institution and whether they have been successful."
Meanwhile, President Donald Trump's prolonged criticism of Fed Chair Jerome Powell reignited speculation about a possible dismissal. According to CFTC-regulated betting platform Kalshi, there&#8217;s a 23% chance Powell could be removed by the end of the year. Powell is legally protected from being removed by Trump.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.1% to $118,590, and Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) added 1.8%, as digital asset demand remained strong following latest policy breakthroughs. 
<h3 class="wp-block-heading">Monday&#8217;s Performance Of Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>% Chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>23,258.14</td>
<td>0.8%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,253.86</td>
<td>0.6%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,335.66</td>
<td>0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,602.93</td>
<td>0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:00 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul class="wp-block-list">
<li>The&nbsp;Vanguard S&amp;P 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VOO#NYSE">VOO</a>) rose 0.6% to $580.15.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 0.6% to $445.86.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;soared 0.8% to $565.17.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 0.6% to $223.58.</li>
<li>The&nbsp;Communication Services&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) outperformed, up 1.2%; the&nbsp;Energy&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.5%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
<ul class="wp-block-list">
<li>Verizon Communications Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VZ#NYSE">VZ</a>) soared 4.7% after reporting stronger-than-expected quarterly results.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) is weighing the sale of several plants, including three idled facilities in Illinois and Pennsylvania. Shares jumped 7.8% to $10.22, with traders viewing the stock as undervalued.</li>
<li>Bruker Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) fell 14% to $57.84 after issuing preliminary second-quarter revenue guidance that came in below Wall Street estimates.</li>
<li>Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) jumped 8.1% after it was announced Friday that the financial technology firm will join the S&amp;P 500 before Wednesday's open. </li>
<li>Stocks scheduled to report earnings Tuesday before the market open include Coca-Cola Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), Philip Morris International Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PM#NYSE">PM</a>), RTX Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>), Danaher Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), Lockheed Martin Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>), Northrop Grumman Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>), General Motors Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>), PACCAR Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCAR#NASDAQ">PCAR</a>), MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) and D.R. Horton Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHI#NYSE">DHI</a>). </li>
</ul>
Now Read
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/economic-data/25/07/46521011/trump-stocks-bonds-foreign-inflows-record">Trump&#8217;s Economy Is Riding A Tsunami Of Inflows — So Much For &#8216;Sell America&#8217; </a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Macro Economic Events

Regulations

$ETH

BRKR

Wall Street Extends Records, Gold Rallies To $3,400: What's Moving Markets Monday?

Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-07-22. Here's what investors need to know before the announcement.
Analysts estimate that Danaher will report an earnings per share (EPS) of $1.64. 
The market awaits Danaher's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.24, leading to a 2.21% increase in the share price on the subsequent day.
Here's a look at Danaher's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.64</td>
<td>2.16</td>
<td>1.57</td>
<td>1.57</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.88</td>
<td>2.14</td>
<td>1.71</td>
<td>1.72</td>
</tr>
<tr>
<td>Price Change %</td>
<td>2.0%</td>
<td>-0.0%</td>
<td>-2.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1753106464_0.png" alt="eps graph" />
<h3>Market Performance of Danaher's Stock</h3>
Shares of Danaher were trading at $190.05 as of July 18. Over the last 52-week period, shares are down 28.65%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Take on Danaher</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Danaher.
A total of 12 analyst ratings have been received for Danaher, with the consensus rating being Outperform. The average one-year price target stands at $238.5, suggesting a potential 25.49% upside.
<h3>Analyzing Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of Thermo Fisher Scientific, Agilent Technologies and IQVIA Hldgs, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Thermo Fisher Scientific, with an average 1-year price target of $539.08, suggesting a potential 183.65% upside.</li>
<li>Analysts currently favor an Neutral trajectory for Agilent Technologies, with an average 1-year price target of $136.0, suggesting a potential 28.44% downside.</li>
<li>Analysts currently favor an Neutral trajectory for IQVIA Hldgs, with an average 1-year price target of $174.0, suggesting a potential 8.45% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Thermo Fisher Scientific, Agilent Technologies and IQVIA Hldgs are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Danaher</td>
<td>Outperform</td>
<td>-0.95%</td>
<td>$3.51B</td>
<td>1.90%</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>Outperform</td>
<td>0.18%</td>
<td>$4.24B</td>
<td>3.05%</td>
</tr>
<tr>
<td>Agilent Technologies</td>
<td>Neutral</td>
<td>6.04%</td>
<td>$866M</td>
<td>3.54%</td>
</tr>
<tr>
<td>IQVIA Hldgs</td>
<td>Neutral</td>
<td>2.46%</td>
<td>$1.30B</td>
<td>4.13%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Danaher ranks at the bottom for Revenue Growth among its peers. It is in the middle for Gross Profit. For Return on Equity, Danaher is at the bottom compared to its peers.
<h3>Unveiling the Story Behind Danaher</h3>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
<h3>Danaher: A Financial Overview</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Danaher's financials over 3 months reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -0.95% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Danaher's net margin is impressive, surpassing industry averages. With a net margin of 16.62%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 1.9%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Danaher's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.22%, the company showcases efficient use of assets and strong financial health.
Debt Management: Danaher's debt-to-equity ratio is below the industry average. With a ratio of 0.32, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/DHR/earnings">To track all earnings releases for Danaher visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insights into Danaher's Upcoming Earnings

Baird analyst Catherine Schulte maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Outperform and raises the price target from $225 to $226.

Baird Maintains Outperform on Danaher, Raises Price Target to $226

Across the recent three months, 12 analysts have shared their insights on Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $238.92, with a high estimate of $275.00 and a low estimate of $215.00. This current average has decreased by 3.17% from the previous average price target of $246.73. 
<img src="https://www.benzinga.com/files/images/story/2025/1752242449_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Danaher. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>Vijay Kumar</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$226.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$215.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Subbu Nambi</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Dan Leonard</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$240.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$225.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$215.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$260.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Tycho Peterson</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$231.00</td>
<td>$258.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Danaher. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Danaher compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Danaher's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/DHR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Danaher analyst ratings.</a>
<h2>About Danaher</h2>
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life science and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
<h3>Key Indicators: Danaher's Financial Health</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Danaher's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -0.95% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 16.62%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Danaher's ROE excels beyond industry benchmarks, reaching 1.9%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Danaher's ROA excels beyond industry benchmarks, reaching 1.22%. This signifies efficient management of assets and strong financial health.
Debt Management: Danaher's debt-to-equity ratio is below the industry average. With a ratio of 0.32, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Significance of Analyst Ratings Explained</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About Danaher Stock

Scotiabank analyst Sung Ji Nam upgrades Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) from Sector Perform to Sector Outperform and announces $275 price target.

Upgrades

Scotiabank Upgrades Danaher to Sector Outperform, Announces $275 Price Target

Danaher's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) short percent of float has risen 4.27% since its last report. The company recently reported that it has 7.75 million shares sold short, which is 1.22% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.19 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Danaher Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752177625_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Danaher has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Danaher's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Danaher's peer group average for short interest as a percentage of float is 7.86%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About Danaher?

Press Releases

Aldevron and Integrated DNA Technologies Manufacture World's First mRNA-based Personalized CRISPR Therapy

Danaher Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine

SCIEX Sets a New Standard in Accurate Mass Quantitation With the ZenoTOF 8600 System and New Software Collaborations

SCIEX and Evosep expand access to standardized proteomics for Pharma and Biotech with new reseller agreement

Software Launches for SCIEX OS Ecosystem to Help Scientists Accelerate Discoveries and Streamline Lab Operations

Danaher Schedules Second Quarter 2025 Earnings Conference Call

Danaher appoints Greg Milosevich to Executive Vice President, Life Sciences

Danaher Appoints Martin Stumpe as Chief Technology and AI Officer

Danaher Reports Second Quarter 2025 Results

Danaher Announces Transition Plan for Chief Financial Officer

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Danaher

Actualités

Dernières nouvelles pour Danaher (NYSE:DHR) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL